Ipamorelin vs Sermorelin: GHRP vs GHRH Comparison

Ipamorelin and sermorelin both stimulate growth hormone (GH) release from the pituitary gland, but they do so through entirely different receptors and on different timescales. Understanding this distinction explains why the two peptides are sometimes paired in research protocols and why the regulatory and safety profiles differ meaningfully.

Receptor Pharmacology

Sermorelin is a GHRH (growth hormone–releasing hormone) analog. It is the first 29 amino acids of endogenous GHRH, the hypothalamic peptide that binds the GHRH receptor on pituitary somatotrophs and stimulates synthesis and release of GH. Because sermorelin acts at the GHRH receptor, GH release remains subject to the body's natural negative-feedback controls (primarily somatostatin), which limits supraphysiological GH peaks.

Ipamorelin is a selective ghrelin receptor (GHSR-1a) agonist — a member of the growth hormone-releasing peptide (GHRP) family that includes GHRP-2, GHRP-6, and hexarelin. The ghrelin receptor is a separate GH-stimulating pathway from GHRH; ghrelin and GHRPs amplify GH release through somatostatin antagonism and direct somatotroph stimulation. Among GHRPs, ipamorelin is notable for its selectivity: it does not meaningfully elevate cortisol or prolactin at typical doses, unlike GHRP-2 and GHRP-6.

GH Release Pattern

Both peptides produce a discrete GH pulse rather than sustained elevation, but the kinetics differ. Sermorelin's half-life is roughly 10–20 minutes; the resulting GH pulse begins within 30–60 minutes and is largely cleared within 2–3 hours. Ipamorelin has a half-life of approximately 2 hours, with a GH pulse beginning within 15–30 minutes and elevated GH for 3–6 hours. Pulsatile GH release more closely mimics endogenous GH secretion than the sustained elevation produced by direct GH (recombinant somatropin) injection.

Combined Use in Research Protocols

Because the two peptides activate different receptor pathways, GHRH analogs (sermorelin, CJC-1295) and GHRPs (ipamorelin, GHRP-2) are commonly studied in combination. The two pathways are synergistic: a GHRH analog promotes GH synthesis and release at the GHRH receptor, while a GHRP simultaneously inhibits somatostatin and amplifies the GH pulse at the ghrelin receptor. The combined GH peak is greater than the sum of the two peptides used alone. This is why CJC-1295 + ipamorelin became one of the most widely studied stack combinations.

Regulatory Status

Sermorelin is FDA-approved as Geref (1997) for diagnosis and treatment of pediatric growth hormone deficiency. Although the original Geref product was withdrawn from the market in 2008 for commercial reasons, sermorelin acetate is currently available through 503A compounding pharmacies as a compounded prescription drug. Adult use for age-related GH decline or anti-aging is off-label.

Ipamorelin is investigational. It has been studied in clinical trials (primarily for postoperative ileus) but did not receive FDA approval for that indication. Per the February 27, 2026 HHS announcement of intent to reclassify certain peptides, ipamorelin's regulatory status may change; verify the current status in your jurisdiction.

Side Effect Profile

Both peptides have favorable safety profiles in published clinical research within their studied dose ranges. Common, mild adverse events include injection-site reactions, transient flushing, headache, and dizziness. Sermorelin's clinical history through Geref provides a longer safety record than ipamorelin's investigational profile. A key advantage of ipamorelin within the GHRP class is its selectivity — it does not meaningfully elevate cortisol or prolactin, which is a relevant differentiator from GHRP-2 and GHRP-6.

Both peptides preserve the body's natural GH feedback regulation, which is generally considered safer than direct supraphysiological GH dosing. However, IGF-1 elevation is dose-dependent for both peptides, and IGF-1 monitoring is appropriate when used in research or clinical settings.